Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Comprehensive Insider Report for ATE

<< Previous

Bullboard Posts

Next >>

Comment by Duster340on Jul 21, 2022 11:39pm

59 Views

Post# 34842227

RE:RE:RE:RE:RE:RE:Comprehensive Insider Report for ATE

MrMugsy wrote: Guys - gotta put these fools on ignore.
They only want to fight and we have to take that away from them.

Stockings and Stutters ,etc .... they don't know anything else. Let's leave them to hug each other.

That would be sweet.

Duster340 Writes: and who else should be on ignore davgro and /pez. do you not get tired of reading there attack posts. never have anything of value to post

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks